Myelofibrosis as a cause of non-cirrhotic portal hypertension
DOI:
https://doi.org/10.47892/rgp.2026.462.2209Keywords:
Primary Myelofibrosis, Idiopathic Noncirrhotic Portal Hypertension, Esophageal VaricesAbstract
Primary myelofibrosis is a chronic myeloproliferative neoplasm characterised by extramedullary hematopoiesis. Portal hypertension represents a significant cause of mortality in these patients. Diagnosis of portal hypertension is typically based on clinical manifestations and is often confirmed by upper gastrointestinal endoscopy, which allows for the identification of oesophageal varices and facilitates endoscopic intervention. Management options include general supportive measures, chemotherapy, splenectomy, and radiation therapy. This report describes a 53-year-old woman with a history of myelofibrosis who presented with abdominal pain and anaemia. Upper gastrointestinal video endoscopy revealed oesophageal varices, and subsequent confirmation of portal hypertension prompted a percutaneous liver biopsy, which demonstrated myelofibrosis. After appropriate management, the patient had a favourable clinical outcome.
Downloads
References
Albillos A, Bañares R, Hernández-Gea V. Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd). Gastroenterol Hepatol. 2025;48(1):502208. doi: 10.1016/j. gastrohep.2024.502208.
Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180-1211. doi: 10.1097/HEP.0000000000000647.
Meena BL, Rudra OS, Sharma D, Sarin SK. Noncirrhotic portal hypertension: current trends and future directions. Curr Opin Gastroenterol. 2025;41(4):271-280. doi: 10.1097/ MOG.0000000000001106.
Fiordaliso M, Marincola G, Pala B, Muraro R, Mazzone M, Di Marcantonio MC, et al. A Narrative Review on Non-Cirrohotic Portal Hypertension: Not All Portal Hypertensions Mean Cirrhosis. Diagnostics (Basel). 2023;13(20):3263. doi: 10.3390/ diagnostics13203263.
Cervantes F. How I treat splenomegaly in myelofibrosis. Blood Cancer J. 2011;1(10):e37. doi: 10.1038/bcj.2011.36.
Gan X, Yu S, Zhu M, Ning B, He S, Xie X, et al. Case report: Primary myelofibrosis presenting with portal hypertension mimicking cirrhosis. Front Med (Lausanne). 2024;11:1375571. doi: 10.3389/fmed.2024.1375571.
Battipaglia G, Polverelli N, Tuffnell J, Chiusolo P, Robin M, Gambella M, et al. Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT. Curr Res Transl Med. 2025;73(1):103476. doi: 10.1016/j.retram.2024.103476.
Lee J, Sung PS, Eom KS, Yang H, Lee SK, Bwa AH, et al. Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms. Clin Mol Hepatol. 2020;26(1):78-82. doi: 10.3350/ cmh.2019.0078.
Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801-821. doi: 10.1002/ajh.26857.
Ali H, Bacigalupo A. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. Am J Hematol. 2024;99(5):938-945. doi: 10.1002/ajh.27274.
Wanless IR, Peterson P, Das A, Boitnott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology. 1990;12(5):1166-74. doi: 10.1002/ hep.1840120515.
Toros AB, Gokcay S, Cetin G, Ar MC, Karagoz Y, Kesici B. Portal hypertension and myeloproliferative neoplasms: a relationship revealed. ISRN Hematol. 2013;2013:673781. doi: 10.1155/2013/673781.
Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore). 1971;50(5):357-420. doi: 10.1097/00005792-197109000- 00001.
Tokai K, Miyatani H, Yoshida Y, Yamada S. Multiple esophageal variceal ruptures with massive ascites due to myelofibrosisinduced portal hypertension. World J Gastroenterol. 2012;18(28):3770-4. doi: 10.3748/wjg.v18.i28.3770.
Glockenberg K, Weinberg EM, Wan DW. A sinister cause of hematemesis. Gastroenterology. 2015;148(3):e5-6. doi: 10.1053/j.gastro.2014.09.033.
Kono Y, Takaki A, Gobara H, Matsuoka K, Nishino M, Okada H, et al. Polycythemia Vera Diagnosed after Esophageal Variceal Rupture. Intern Med. 2015;54(18):2395-9. doi: 10.2169/ internalmedicine.54.4687.
Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39(2):280-2. doi: 10.1002/hep.20062.
Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25(2):281-90. doi: 10.1016/j. bpg.2011.02.009.
Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7(2):141-55. doi: 10.1586/egh.12.83.
Vuille-Lessard É, Rodrigues SG, Berzigotti A. Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease. Clin Liver Dis. 2021;25(2):253-289. doi: 10.1016/j.cld.2021.01.005.
Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study. Hepatology. 2016;64(6):2173-2184. doi: 10.1002/hep.28824.
Mangal R, Jamil M, Nasser Z, Purtell JP. A Case of Non-cirrhotic Portal Hypertension in a Patient With Primary Myelofibrosis Disease. Cureus. 2023;15(8):e44313. doi: 10.7759/cureus.44313.
Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954- 1970. doi: 10.1182/blood.2022017423.
RUXOLITINIB en Mielofibrosis primaria y secundaria. Informe para la Guía Farmacoterapéutica de Hospitales de Andalucía. Programa MADRE versión 4.0. Andalucía; 2012.
Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023;16(1):82. doi: 10.1186/ s13045-023-01471-z.
Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-7. doi: 10.1038/leu.2016.148.
Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006;106(9):1974-84. doi: 10.1002/ cncr.21827.
Chen Y, Kong BB, Yin H, Liu H, Wu S, Xu T. Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report. World J Clin Cases. 2024;12(15):2621-2626. doi: 10.12998/wjcc.v12.i15.2621.
Sherman MS, Samore WR, Pratt DS. Myelofibrosis and Portal Hypertension: The Case for Primary Variceal Screening. ACG Case Rep J. 2020;7(2):e00333. doi: 10.14309/ crj.0000000000000333.
Panda A, Chandrashekhara SH, Nambirajan A, Mishra P. Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: initial presentation and 2 years follow-up. BMJ Case Rep. 2016;2016:bcr2016217854. doi: 10.1136/bcr-2016-217854.
Doki N, Irisawa H, Takada S, Sakura T, Miyawaki S. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med. 2007;46(4):187-90. doi: 10.2169/internalmedicine.46.1768.
Biss T, Hamilton P. Myelofibrosis and angiodysplasia of the colon: another manifestation of portal hypertension and massive splenomegaly? J Clin Pathol. 2004;57(9):999-1000. doi: 10.1136/jcp.2003.015479.
Angermayr B, Cejna M, Schoder M, Wrba F, Valent P, Gangl A, et al. Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood. 2002;99(11):4246-7. doi: 10.1182/blood-2002-01-0282.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Juan José Quiroz-Leyva, Edgar Fermín Yan-Quiroz, José Richard Tenazoa-Villalobos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 